Energy News / Shareholders Foundation, Inc.

NASDAQ:KPTI Shareholder Notice: Deadline on September 23, 2019 in Lawsuit Against Karyopharm Therapeutics Inc.

Via: ReleaseWire

Updated 11:30 AM CDT, Mon, September 09,2019

A Deadline is coming up on September 23, 2019 in the lawsuit for certain investors in Karyopharm Therapeutics Inc. (NASDAQ: KPTI).

San Diego, CA -- (SBWIRE) -- 09/09/2019 -- The Shareholders Foundation announces that a deadline is coming up on September 23, 2019 in the lawsuit filed for certain investors of Karyopharm Therapeutics Inc. (NASDAQ: KPTI) over alleged securities laws violations by Karyopharm Therapeutics Inc.

Investors who purchased shares of Karyopharm Therapeutics Inc. (NASDAQ: KPTI) have certain options and there are strict and short deadlines running. Deadline: September 23, 2019. NASDAQ: KPTI stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The plaintiff alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Karyopharm Therapeutics Inc. (NASDAQ: KPTI) common stock during the time period of March 2, 2017 and February 22, 2019, and violations of Sections 11, 12(a)(2), and 15 of the Securities Act of 1933 on behalf of all persons who purchased or otherwise acquired Karyopharm Therapeutics Inc. (NASDAQ: KPTI common stock in or traceable to the Company's public offerings of common stock conducted on or around April 28, 2017 and May 7, 2018. More specifically, the plaintiff alleges that the Defendants' material misrepresentations and omissions center on Defendants' claims regarding results from clinical trials for selinexor's treatment of patients with certain types of blood cancer, that the, Defendants claimed that selinexor studies showed that selinexor was "well-tolerated" by patients and explained that there were "no new clinically significant adverse events in the patients receiving selinexor", and that the Company repeatedly touted the commercial prospects for selinexor and consistently described selinexor as having a "predictable and manageable tolerability profile" and a "very nice safety profile", while in reality, selinexor was unsafe with limited efficacy.

Those who purchased shares of Karyopharm Therapeutics Inc. (NASDAQ: KPTI) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

For more information on this press release visit:
http://www.sbwire.com/press-releases/nasdaqkpti-shareholder-notice-deadline-on-september-23-2019-in-lawsuit-against-karyopharm-therapeutics-inc-1259110.htm

Media Relations Contact
Michael Daniels
1-858-779-1554
Email: Click to Email Michael Daniels
Web: http://www.ShareholdersFoundation.com